Similar articles

• Serum immunosuppressive activity of azathioprine in normal subjects and patients with liver diseases.

  Bach JF, Dardenne M. Bach JF, et al. Proc R Soc Med. 1972 Mar;65(3):260-3. doi: 10.1177/003591577206500316. Proc R Soc Med. 1972. PMID: 4563301 Free PMC article. No abstract available.
• HPLC analysis of azathioprine metabolites in red blood cells, plasma and urine in renal transplant recipients.

  Weller S, Thürmann P, Rietbrock N, Gossmann J, Scheuermann EH. Weller S, et al. Int J Clin Pharmacol Ther. 1995 Dec;33(12):639-45. Int J Clin Pharmacol Ther. 1995. PMID: 8963480 Clinical Trial.
• [Determination of active metabolites of immunosuppressive agents in the serum. Application to azathioprine].

  Bach JF, Dardenne M, Bach MA. Bach JF, et al. Nouv Presse Med. 1972 Oct 7;1(35):2293-8. Nouv Presse Med. 1972. PMID: 5085890 French. No abstract available.
• Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine.

  Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Gardiner SJ, et al. Adverse Drug React Toxicol Rev. 2000 Dec;19(4):293-312. Adverse Drug React Toxicol Rev. 2000. PMID: 11212460 Review. No abstract available.
• Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

  Gearry RB, Barclay ML. Gearry RB, et al. J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. doi: 10.1111/j.1440-1746.2005.03832.x. J Gastroenterol Hepatol. 2005. PMID: 16048561 Review.